Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajay Ajmani

Internal Medicine Sanford, NC Medical Doctor

NPI 1811998867 CMS profile 500645

111 Dennis Dr, Suite 121, Sanford, NC 27330

Open in the dashboard

General payments

$6,319

355 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajay Ajmani of Sanford, NC is reported in the CMS Open Payments database as having received $6,319 across 355 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $501 23
2024 General $925 45
2023 General $815 39
2022 General $1,138 64
2021 General $1,019 53
2020 General $903 73
2019 General $1,018 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajay Ajmani
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ajay Ajmani were reported at $501. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ajay Ajmani Internal Medicine median Middle half National median
2019 $1,018 $159 $48–$570 $163
2020 $903 $119 $33–$402 $114
2021 $1,019 $135 $37–$521 $132
2022 $1,138 $141 $42–$496 $149
2023 $815 $149 $45–$519 $160
2024 $925 $154 $47–$537 $164
2025 $501 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $840 52 payments
  2. Amgen Inc. $708 35 payments
  3. Janssen Biotech, Inc. $454 23 payments
  4. AstraZeneca Pharmaceuticals LP $447 30 payments
  5. Pfizer Inc. $409 24 payments
  6. AbbVie, Inc. $339 20 payments
  7. Indivior Inc. $317 16 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $306 18 payments
  9. UCB, Inc. $282 9 payments
  10. Mallinckrodt Hospital Products Inc. $281 8 payments
  11. Other $1,937 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,185 351 payments
  2. Education $135 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $666 43 payments
  2. RYBELSUS $635 41 payments
  3. XIFAXAN $306 18 payments
  4. Cimzia $282 9 payments
  5. ACTHAR $281 8 payments
  6. SIMPONI ARIA $280 14 payments
  7. FARXIGA $279 18 payments
  8. SIMPONI $270 14 payments
  9. XELJANZ $268 16 payments
  10. Enbrel $251 11 payments
  11. Other $4,643 268 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 134 drugs

Part D claims

7,084

Median for Internal Medicine: 777

Drug cost

$1,195,011

Median for Internal Medicine: $73,373

Branded share of claims

21.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 41 $304,635
Humira Pen Adalimumab Brand 28 $199,894
Remicade Infliximab Brand 17 $96,594
Enbrel Etanercept Brand 12 $92,402
Otezla Apremilast Brand 13 $62,787
Rybelsus Semaglutide Brand 55 $60,864
Actemra Actpen Tocilizumab Brand 11 $60,013
Ozempic Semaglutide Brand 42 $37,513
Eliquis Apixaban Brand 65 $32,716
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 171 $19,431

The 10 drugs with the highest cost, of 134 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$189,541

Of which drugs: $64,694

Medicare patients

145

Average age 71

Services billed

4,858

87 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 56%
Diabetes 33%
Depression 31%
Alzheimer's or dementia 30%
Heart failure 26%
Chronic kidney disease 24%
Ischemic heart disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 39 39 $3,164

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IDACIO
  • Fresenius Kabi USA, LLC $131
$131 — —
RYBELSUS
  • Novo Nordisk Inc $115
$115 55 —
Ozempic
  • Novo Nordisk Inc $115
$115 42 —
Enbrel
  • Amgen Inc. $94
$94 53 —
TAVNEOS
  • Amgen Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

355 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record